TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04630457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Meridium® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RoFT® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RoFT® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
Study: NCT04182087

Intervention type: BEHAVIORAL
Intervention: Cognitive tasks
Description: Attention, language, memory, decision-making or executive functions
Study: NCT02305082

Intervention type: OTHER
Intervention: Fast-track group
Description: Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
Study: NCT01801930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 0.3 mg of each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 1 mg of each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 3 mg of each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 6 mg of each
Study: NCT03841019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
Study: NCT03702400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 100 mcg
Description: Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 mcg
Description: Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
Study: NCT03200587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
Study: NCT01720615

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Propofol / Remifentanil
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study: NCT00730951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: 500mg Capsulated Ground Dried Korean Red Ginseng Root

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: 500mg Capsulated Ground Dried Korean Red Ginseng Root

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Starch
Description: 500mg Capsulated Corn Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Starch
Description: 500mg Capsulated Corn Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Starch
Description: 500mg Capsulated Corn Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Starch
Description: 500mg Capsulated Corn Starch
Study: NCT03042520

Intervention type: OTHER
Intervention: Observation only

Intervention type: OTHER
Intervention: Observation only
Study: NCT01552018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Saxagliptin 5 mg, 1 tablet per day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet per day for 3 months.
Study: NCT04582344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac
Description: Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
Study: NCT00669461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone 24 mcg BID orally for 4 weeks
Study: NCT00959920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling catheter
Description: Indwelling bladder catheter will remain in place until time of delivery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent straight catheterization
Description: intermittent straight catheterization will be performed on an as needed basis until time of delivery.
Study: NCT05013606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen water
Description: This is an over the counter pill supplement that is dissolved in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen water
Description: This is an over the counter pill supplement that is dissolved in water.
Study: NCT01906060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q Intubation Laryngeal Mask
Description: Patients will be intubated using the Air-Q Laryngeal Mask.
Study: NCT00707590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-767778 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-767778 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-767778 or Placebo
Study: NCT00105794

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Psychiatric Advance Directives intervention
Study: NCT05351372

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-low dose protocol

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose protocol
Study: NCT02485041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered
Study: NCT02220491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy
Description: Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-brain radiotherapy
Description: Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
Study: NCT02700867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIO
Description: Intraosseous access device NIO (Defibtech)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIO
Description: Intraosseous access device NIO (Defibtech)
Study: NCT02215044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, intravenous
Study: NCT04658849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 Mg Oral Tablet
Description: Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo tablet
Description: Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
Study: NCT03874156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
Study: NCT00908947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA followed by placement of LifeStent® Vascular Stent
Description: PTA followed by placement of LifeStent® Vascular Stent
Study: NCT00169780

Intervention type: RADIATION
Intervention: High definition helical CT (64 head scanner)
Description: Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs.
Study: NCT04475224

Intervention type: DRUG
Group type: OTHER
Intervention: KP-100IT
Description: Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
Study: NCT02138331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC exosomes.
Description: Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
Study: NCT04346524

Intervention type: OTHER
Intervention: sampling of microbiome
Description: women will sample from vagina, feces, and saliva during pregnancy
Study: NCT01141933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-existential intervention
Description: Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-existential intervention
Description: Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: This group receive the usual treatment only.
Study: NCT01764451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT04594330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: virgin coconut oil (VCO)
Description: 15 mL of VCO twice a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 15 mL of placebo twice a day for 14 days
Study: NCT00504114

Intervention type: PROCEDURE
Intervention: ACL Reconstruction Surgery

Intervention type: PROCEDURE
Intervention: Cartilage Resurfacing Surgery

Intervention type: PROCEDURE
Intervention: Total Knee Replacement
Study: NCT01092806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
Study: NCT04459988

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Description Needed
Study: NCT03441360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous infusion
Study: NCT00753168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-730 ophthalmic solution
Description: one eye drop twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol maleate ophthalmic solution
Description: one eye drop twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OT-730 placebo
Description: one eye drop twice daily
Study: NCT03639324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose combination 1-1
Description: 100 mg QD of idelalisib + 100 mg QD of venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose combination 1-2
Description: 100 mg QD of idelalisib + 200 mg QD of venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose combination 1-3
Description: 100 mg BID of idelalisib + 200 mg QD of venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose combination 1-4
Description: 150 mg BID of idelalisib + 200 mg QD of venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-Trial: Dose combination 2-1
Description: 100 mg BID of idelalisib + 100 mg QD of venetoclax
Study: NCT01720615

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sevoflurane / Remifentanil
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study: NCT03387904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Irinotecan
Description: Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
Study: NCT00661921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 108
Description: IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 108
Description: IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
Study: NCT03387904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan Day 1,8 ivgtt
Study: NCT01746732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration
Study: NCT00661921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 108
Description: IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AMG 108 volume matching placebo
Study: NCT00891423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem short infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem extended infusion
Study: NCT03979833

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
Study: NCT02589886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and self-help internet intervention
Description: The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
Study: NCT02146976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: introvenious infusion of propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
Study: NCT02306837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-CY-E
Description: mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
Study: NCT00004079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SarCNU
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02235584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone are given dexamethasone tablets of 2mg twice daily.
Study: NCT01556282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
Study: NCT04526652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Evaluating anxiety score in both arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Evaluating anxiety score in both arms
Study: NCT02408445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate 200mg/ml
Description: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
Study: NCT02582788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bathing Additive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bathing Additive
Study: NCT01182662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived MSCs and cyclosporin A
Description: 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A
Description: cyclosporin A 5mg/kg po for 12 months
Study: NCT02577224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment
Description: Please see Intervention Arm
Study: NCT00991510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Myfenax)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Myfenax)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Cellcept)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Cellcept)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.